153 related articles for article (PubMed ID: 14983417)
1. Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in Japan.
Uemura S; Homma Y
Neurourol Urodyn; 2004; 23(2):94-100. PubMed ID: 14983417
[TBL] [Abstract][Full Text] [Related]
2. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder.
Homma Y; Uemura S
BJU Int; 2004 May; 93(7):1009-13. PubMed ID: 15142153
[TBL] [Abstract][Full Text] [Related]
3. Reliability and validity of the King's Health Questionnaire for lower urinary tract symptoms in both genders.
Okamura K; Nojiri Y; Osuga Y
BJU Int; 2009 Jun; 103(12):1673-8. PubMed ID: 19154505
[TBL] [Abstract][Full Text] [Related]
4. Psychometric properties and validation of the German-language King's Health Questionnaire in women with stress urinary incontinence.
Bjelic-Radisic V; Dorfer M; Tamussino K; Greimel E
Neurourol Urodyn; 2005; 24(1):63-8. PubMed ID: 15578627
[TBL] [Abstract][Full Text] [Related]
5. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
6. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
Kelleher CJ; Kreder KJ; Pleil AM; Burgess SM; Reese PR
Am J Manag Care; 2002 Dec; 8(19 Suppl):S616-30. PubMed ID: 12516956
[TBL] [Abstract][Full Text] [Related]
7. Psychometric validation of the Japanese version of the International Consultation on Incontinence Questionnaire-Short Form.
Gotoh M; Homma Y; Funahashi Y; Matsukawa Y; Kato M
Int J Urol; 2009 Mar; 16(3):303-6. PubMed ID: 19207608
[TBL] [Abstract][Full Text] [Related]
8. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
Coyne KS; Matza LS; Kopp Z; Abrams P
Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
10. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM
BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire.
Haab F; Richard F; Amarenco G; Coloby P; Arnould B; Benmedjahed K; Guillemin I; Grise P
Urology; 2008 Apr; 71(4):646-56. PubMed ID: 18313122
[TBL] [Abstract][Full Text] [Related]
12. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
13. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
Colman S; Chapple C; Nitti V; Haag-Molkenteller C; Hastedt C; Massow U
Urology; 2008 Oct; 72(4):803-7. PubMed ID: 18722655
[TBL] [Abstract][Full Text] [Related]
14. Reliability of a Thai version of King's Health Questionnaire in Thai females with overactive bladder symptoms.
Kochakarn W; Pummangura N; Kijvikai K; Viseshsindh W; Sukying C; Lertsithichai P
J Med Assoc Thai; 2005 Nov; 88(11):1526-34. PubMed ID: 16471097
[TBL] [Abstract][Full Text] [Related]
15. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire.
Clayson D; Wild D; Doll H; Keating K; Gondek K
BJU Int; 2005 Aug; 96(3):350-9. PubMed ID: 16042729
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
17. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
18. The development of a questionnaire to measure the severity of symptoms and the quality of life before and after surgery for stress incontinence.
Kulseng-Hanssen S; Borstad E
BJOG; 2003 Nov; 110(11):983-8. PubMed ID: 14592582
[TBL] [Abstract][Full Text] [Related]
19. Which questionnaire? A psychometric evaluation of three patient-based outcome measures used to assess surgery for stress urinary incontinence.
Reid FM; Smith AR; Dunn G
Neurourol Urodyn; 2007; 26(1):123-8. PubMed ID: 16998861
[TBL] [Abstract][Full Text] [Related]
20. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
